RxDoctor Payments Data

Miguel Sabedra, MD

Family Medicine · Marlow, OKNPI 1003881921

Payments from drug & device makers

$303in general payments, 2019–2025

Across 13 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$110
  • Otsuka America Pharmaceutical, Inc.$38
  • Boehringer Ingelheim$34
  • Lundbeck LLC$20
  • GSK$20
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$21170%
  • Education$9230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$303 in reported general payments places this provider in the 45th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$70,076
Medicare patients
109
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin182$136,567
EliquisApixaban177$95,245
JanuviaSitagliptin Phosphate55$57,948
OzempicSemaglutide61$56,469
XareltoRivaroxaban37$28,014
NuplazidPimavanserin Tartrate11$27,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$22,507
Xtampza ErOxycodone Myristate12$12,921
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen371$11,212
TradjentaLinagliptin27$8,326
Fiasp FlextouchInsulin Aspart (Niacinamide)16$8,124
Sucralfate46$5,910
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$5,846
Potassium Chloride366$5,240
Tresiba Flextouch U-100Insulin Degludec13$5,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$34$144,893209 claims
PfizerEliquis$17$95,245177 claims
Novo NordiskOzempic$15$56,46961 claims
GSKTrelegy Ellipta$20$22,50724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Marlow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →